Overview

A Study to Evaluate the Pharmacokinetics and Safety of BR3409 and Co-administration of BR3409-1 and BR3409-2 in Healthy Volunteers Under Fasting Conditions

Status:
COMPLETED
Trial end date:
2025-01-26
Target enrollment:
Participant gender:
Summary
The purpose of this clinical study is to evaluate the pharmacokinetics and safety of BR3409 and co-administration of BR3409-1 and BR3409-2 in healthy volunteers Under Fasting Conditions
Phase:
PHASE1
Details
Lead Sponsor:
Boryung Pharmaceutical Co., Ltd